Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Neoplasms 9Recurrence 4Breast Neoplasms 4Advanced Solid Tumors 4Solid Tumor 3Lymphoma, Non-Hodgkin 3Lymphoma 3Carcinoma, Non-Small-Cell Lung 3Triple Negative Breast Neoplasms 2Ovarian Neoplasms 2Neoplasm Metastasis 2Multiple Myeloma 2Medical Oncology 2Lymphoma, Follicular 2Uterine Cervical Neoplasms 1Tuberous Sclerosis 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumours 1Solid Tumour 1Solid Tumors 1Solid Tumor, Adult 1Small Cell Lung Carcinoma 1Sarcoma, Synovial 1Sarcoma 1Rhabdoid Tumor 1Refractory or Relapsed Solid Tumors 1Prostatic Neoplasms 1Polycystic Ovary Syndrome 1Pancreatic Neoplasms 1Mesothelioma 1

Interventions

darolutamide 1Rifampin 1Itraconazole 1Hydroxychloroquine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Refractory or Relapsed Solid Tumors × Itraconazole × Clear all
NCT07620041 2026-06-02

QLC5508 in Advanced Solid Tumors:: C-QTc, Pharmacokinetics (PK) Comparisons and Drug-drug Interaction

Qilu Pharmaceutical Co., Ltd.

Phase 1 Not yet recruiting
48 enrolled
Other solid neoplasm

Refractory or Relapsed Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡